A study of radiographic changes and clinical outcomes in patients with Interstitial-lung-diseases treated with PD-1 inhibitors (pembrolizumab and nivolumab)
Latest Information Update: 03 Jul 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Interstitial lung diseases
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 03 Jul 2020 New trial record
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society